Clinical trial · Observational
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
NCT01380587CI-TRIAL-00011930XCL1completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Acute Lymphoblastic Leukemia
- description
- We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
Primary outcomes (2)
- measure
- Number of patients with poor prognosis and high levels of XCL1
- timeFrame
- 3 months
- description
- Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
- measure
- Number of patients with poor prognosis and high levels of cytokines
- timeFrame
- 3 months
- description
- Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
Show eligibility criteria text
Inclusion Criteria: Patients with newly diagnosed acute lymphoblastic leukemia . Exclusion Criteria: * Patients with prior treatment with chemotherapeutic agents. * Patients treated with immunosuppressants. * Patients under 12 months old. * Patients with a diagnosis or history of autoimmune diseases. * Patients with a diagnosis or history of immunosuppressive diseases. * Patients who do not agree to sign a Letter of Informed Consent.
References
Publications (6)
- BACKGROUNDHuang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem Biophys Res Commun. 2001 Feb 23;281(2):378-82. doi: 10.1006/bbrc.2001.4363. PMID 11181058
- BACKGROUNDTaub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol. 1994 Aug;1(4):229-46. PMID 7584498
- BACKGROUNDOppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617-48. doi: 10.1146/annurev.iy.09.040191.003153. PMID 1910690
- BACKGROUNDBazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 Feb 13;385(6617):640-4. doi: 10.1038/385640a0. PMID 9024663
- BACKGROUNDRollins BJ. Chemokines. Blood. 1997 Aug 1;90(3):909-28. No abstract available. PMID 9242519
- BACKGROUNDStievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol. 2003 Nov 1;171(9):4528-38. doi: 10.4049/jimmunol.171.9.4528. PMID 14568926